← 返回前沿论文

抑制 GDF15/GFRAL:实体瘤治疗的新机遇

英文原题:Inhibition of GDF15/GFRAL: A novel opportunity for the treatment of solid tumors.

PubMed 2025/12/26(内容时间) Int Immunopharmacol Q1 · IF 5.6(JCR 2025)

研究概要

生长分化因子 15(GDF15)是 TGF- 超家族成员,在肿瘤生物学中发挥多方面且依赖背景的作用。

中文摘要

生长分化因子15(GDF15)是TGF-β超家族成员,在癌症生物学中发挥多方面且依赖情境的作用。本综述整合了有关GDF15双重作用的现有证据,重点阐述其功能如何从癌变早期的肿瘤抑制介质转变为晚期疾病中强效的肿瘤进展驱动因子。GDF15可通过多种机制重塑免疫抑制性肿瘤微环境,包括抑制细胞毒性T细胞和自然杀伤(NK)细胞浸润、促进调节性T细胞(Treg)分化,以及损害树突状细胞成熟和功能。综述还阐明GDF15/GFRAL-RET信号轴在癌症恶病质中的核心作用:该通路通过下丘脑调节食欲,并在全身诱导肌肉萎缩和脂肪组织丢失。不断积累的数据提示,GDF15是连接细胞衰老、线粒体应激和抗癌治疗耐药的关键节点。最后,本文讨论了新兴治疗策略,包括GDF15中和抗体、GFRAL拮抗剂和选择性RET抑制剂;这些方法旨在同时抑制肿瘤生长并缓解恶病质,为晚期实体瘤管理提供有前景的综合策略。

展开英文摘要原文

Growth differentiation factor 15 (GDF15), a member of the TGF- superfamily, exerts multifaceted and context-dependent roles in cancer biology. This review integrates current evidence on the dual nature of GDF15, emphasizing its functional transition from a tumor-suppressive mediator during early carcinogenesis to a potent driver of tumor progression in advanced disease. We highlight its capacity to reshape the immunosuppressive tumor microenvironment through multiple mechanisms: suppression of cytotoxic T cell and natural killer (NK) cell infiltration, promotion of regulatory T cell (Treg) differentiation, and impairment of dendritic cell maturation and function. Additionally, we delineate the central role of the GDF15/GFRAL-RET signaling axis in mediating cancer cachexia via hypothalamic regulation of appetite and systemic induction of muscle atrophy and adipose tissue loss. Accumulating data position GDF15 as a critical node linking cellular senescence, mitochondrial stress, and resistance to anticancer therapies. Finally, we discuss emerging therapeutic approaches-such as GDF15-neutralizing antibodies, GFRAL antagonists, and selective RET inhibitors-that are designed to concurrently suppress tumor growth and mitigate cachexia, offering a promising integrated strategy for the management of advanced solid tumors.

论文信息

作者
Zhang P、Liu Y、Yang H、Li J、Fan G、Bai H、Cao X、Li Y
第一作者单位
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.China
通讯作者单位
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China; Department of Hepatobiliary Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China. Electronic address: liyanjun@sxbqeh.com.cn.China
文献类型
综述
期刊
International immunopharmacology2026 Feb 1
原文标识
PubMed 41455368 · DOI 10.1016/j.intimp.2025.116109